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Abstract 
HL60 cells are human promyeloid cells that can be induced to differentiate by physiological stimuli (e.g. all-trans retinoic acid 
(ATRA), 1 a,25-dihydroxyvit~min D 3 (D3), granulocyte colony-stimulating factor (G-CSF)) and by non-physiological agents such as 
dimethysulphoxide (DMSO) and protein kinase C-activating phorbol esters. The sensitivity of HL60 cells to physiological differentiating 
agents, but not to DMSO, is enhanced when cells are exposed to 'anti-inflammatory agents' (e.g. indomethacin) or are 'primed' 
(pretreated) with a small amount of ATRA: alone, neither treatment induces differentiation. We earlier suggested that indomethacin might 
act by inhibiting the endogenous formation of a differentiation-suppressing prostanoid (Bunce, C.M., et al. (1994) Leukemia 8, 595-604). 
Studies of the formation of prostanoids by HL60 cells and of the effects of prostanoids on these cells failed to identify any prostanoid that 
could be implicated in sensitization by indomethacin. 3a-Hydroxysteroid dehydrogenase (3a-HSD) is another target of such 'anti-in- 
flammatory agents'. Steroid inhibitors of 3a-HSD sensitized HL60 cells to inducers of differentiation in a manner similar to 
indomethacin. 3 t~-HSD is a member of the aldoketoreductase enzyme family, which comprises many enzymes of similar size and primary 
sequence. A protein that was recognised by an antiserum to 3a-HSD was found in HL60 cells, but the cells showed no detectable 
3a-HSD activity. The 3a-HSD-like protein was strikingly down-regulated by 'priming' doses of ATRA. When treatment with a 
differentiation-sensitizing 'anti-inflammatory agent' or steroid was combined with ATRA 'priming',  the effects of the different treatments 
were not additive: the resulting increase in sensitivity equalled that achievable by either treatment alone. We conclude that interference 
with a single intracellular regulatory mechanism underlies the increases in sensitivity of ceils to differentiating agents that are caused by 
anti-inflammatory agents, by certain steroids and by 'priming' with ATRA. Decreased activity of a yet-to-be-identified member of the 
aldoketoreductase family of dehydrogenases is likely to be a central feature of a previously unrecognised mechanism that controls the 
responsiveness of cells to environmental stimuli such as retinoids and D 3. 
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1. Introduction 
Several myeloid cell culture models, including the hu- 
man promyelocytic leukaemia-derived cell line HL60, have 
been demonstrated to differentiate towards monocytes or 
neutrophils in response to agents that include 1 ce,25-dihy- 
droxyvitamin D 3 (D 3 [1-4]), all-trans retinoic acid (ATRA 
[5-8]) and 9-cis retinoic acid [7-9]. These agents are 
believed to exert these activities by their interaction with 
specific nuclear receptors (RAR-a, -/3 and -y; RXR -c~, 
-/3 and -y  and VDR) which act as homo- and hetero-di- 
meric transcription regulators (for reviews see [10-12]). 
We recently showed that the 'anti-inflammatory agents' 
indomethacin and dexamethasone potentiate ATRA-in- 
duced neutrophilic differentiation and that indomethacin 
potentiates D3-induced monocytic differentiation of HL60 
cells. We suggested that these agents might prevent the 
ceils from making a differentiation-suppressive prostanoid, 
so enhancing their responsiveness to inducers of differenti- 
ation [13]. Since indomethacin did not potentiate differenti- 
ation in response to dimethysulphoxide (DMSO), it must 
influence a pathway that modulates differentiation rather 
than interfere with a step that is central to differentiation. 
Therefore, the above studies have revealed a previously 
unrecognised mechanism by which cells are able to control 
their responsiveness to environmental stimuli such as 
retinoids and D 3. An understanding of this pathway will be 
essential to understanding the role of retinoids and D 3 in 
governing cell differentiation and may provide the means 
to improve differentiation therapy for conditions such as 
acute leukaemias and myelodysplasias. We have since 
discovered other agents that potentiate HL60 cell differen- 
tiation and have analysed the prostanoids formed by differ- 
entiating HL60 cells. The results of these studies, reported 
here, indicate that the unidentified regulator of differentia- 
tion that is made by HL60 cells is not a cyclooxygenase- 
generated prostanoid. 
We have also shown that 'priming' of HL60 cells with 
concentrations of ATRA lower than those needed to re- 
strain proliferation or to promote significant neutrophil 
differentiation also potentiates the response of HL60 cells 
to D 3 [8]. We offer evidence that the differentiation-prim- 
ing effects of ATRA pretreatment and that the effects of 
the drugs which potentiate HL60 cell differentiation are 
consequences of the functional inactivation of a single 
intracellular component. This shared intracellular target 
appears to be a member of the aldoketoreductase family of 
dehydrogenases. 
2. Materials and methods 
2.1. Materials 
D 3 (a gift from Dr. Lise Binderup; Leo Pharmaceuti- 
cals) was stored in the dark at - 20°C  as a stock solution 
of 4 mM in isopropanol. 1 mM ATRA (Sigma, Dorset, 
UK) was freshly prepared in dimethylsulphoxide (DMSO) 
and kept at 4°C in the dark. Medroxyprogesterone acetate 
(17a-acetoxy-6a-methylprogesterone) was from Sigma. 
Recombinant hG-CSF (Neuprogen, Amgen Pharmaceuti- 
cals) was stored in the dark at 4°C at 30 m g / m l  in sterile 
PBS containing 0.1% bovine serum albumin. TBA 
(Cascade Biochemicals, Reading, Berks, UK) and dexa- 
methasone (Sigma) were dissolved at 100 mM in DMSO, 
caffeic acid (Sigma) at 10 mM in RPMI 1640, aspirin 
(Sigma) at 0.75 M in ethanol, and indomethacin (Sigma) at 
20 mM in DMSO. The TBA solution was stored at - 20°C 
and dexamethasone at 4°C. Fresh solutions were prepared 
for each experiment. PGA 2, PGE 2, PGF2~ and carbo- 
cyclic thromboxane A 2 (Sigma) were dissolved in ethanol 
(15 mM, stored at - 20°C  in the dark). At the maximum 
concentrations used, the solvents had no effect on differen- 
tiation. 
2.2. Maintenance o f  HL60 cells, induction o f  differentia- 
tion towards monocytes or neutrophils, and assessment of  
differentiation 
Stocks of HL60 cells were maintained in exponential 
growth in RPMI 1640 medium (Gibco, Paisley, UK) con- 
taining 100 U / m l  penicillin and 100 /xg/ml streptomycin 
(Gibco), supplemented either with 10% ( v / v )  heat-in- 
activated fetal calf serum (Gibco) or with a serum replace- 
ment containing insulin, transferrin, selenium dioxide, 
bovine serum albumin and linoleic acid (ITS + ; Stratec, 
Luton, UK). The cells were maintained between 2 .5-12.  
105 cel ls /ml by feeding with the appropriate medium. 
HL60 stocks grown in ITS + were derived from the 
FCS-maintained cells and had been maintained without 
serum for > 3 yr. Cultures were maintained at 37°C in a 
humidified atmosphere containing 5% CO 2. Both serum 
free and FCS-maintained cells were mycoplasma free. 
This study centered on D3-induced monocytic differen- 
tiation of HL60 cells maintained in ITS + ,  with a smaller 
number of studies on neutrophilic differentiation of 
serum-maintained cells in response to ATRA (with or 
without G-CSF). For these experiments, exponentially 
growing cells were adjusted to 2.5.105 cel ls /ml and set 
up as 4 ml cultures in 25 cm 2 tissue culture flasks (Nunc, 
Paisley, UK). Cell densities were kept between 2.5.105 
and 12. l0 s cel ls /ml  by adding medium (containing in- 
ducers of differentiation when appropriate). 
Differentiation was assessed by the acquisition of the 
ability to phagocytose complement coated yeasts, the ex- 
pression of a-naphthyl acetate esterase (ANAE) activity 
and in some experiments by either the ability to reduce 
nitroblue tetrazolium (NBT) or expression of CD 11 b anti- 
gen. Our procedures for each of these assays have been 
described in detail in our previous studies [8,13,14]. Cells 
expressing mature cell markers, but which were not 
ANAE-positive, were regarded as having differentiated 
C.M. Bunce et al. / Biochimica et Biophysica Acta 1311 (1996) 189-198 191 
towards neutrophils. Those which developed ANAE posi- 
tivity in combination with the other markers were regarded 
as having differentiated towards monocytes. This assess- 
ment was supported by analysis of cell morphology. 
[14C]DHT was used as substrate and for 20a-HSD, 
[14C]progesterone was used. Reaction products were sepa- 
rated by TLC, as described by Penning et al. [20] and 
Garland and Dexter [21] and revealed by autoradiography. 
2.3. Analysis of arachidonate metabolites formed by HL60 
cells 3. R e s u l t s  
Cells were labeled with [14C]arachidonic acid [15]. 
Briefly, 1.107 cells from uninduced or differentiating 
cultures were pelleted and resuspended in 1 ml PBS 
containing 0.5 /~Ci [l-14C]arachidonic acid (50-62 
mCi/mmol; Amersham International, UK). After 20 min. 
at 37°C, the ceils were pelleted at 4°C and the supernatant 
was removed. The ceils were resuspended in 1 ml fresh 
PBS and the cell suspensions and the harvested super- 
natants were extracted separately [15]. The extracts were 
dried under vacuum, lipids were dissolved in 20/xl CHC13, 
spotted onto polyester-backed PE-SIL G silica TLC plates 
(250 /xM layer, 20 × 20 cm, Whatman, Maidstone, Kent, 
UK) and separated using solvent C of Hurst et al. [16] 
( c h l o r o f o r m / m e t h a n o l / g l a c i a l  acetic ac id /wa te r ;  
90:8:1:0.8, by vol.). Authentic arachidonic acid, thrombox- 
ane B E, HHT, and prostaglandins E 2, F2,, D 2 and A 2 
were included on each plate. The standards were visualised 
with 12 vapour, their po,;itions outlined and the plates 
autoradiographed using Hyperfilm-fl Max (Amersham) at 
- 70°C. 
2.4. Immunoblotting of 3a.-HSD 
HL60 cell e x t r a c t s  (1(I 6 cells) and rat liver extracts 
(approximately 3 mm 3 of tissue) were prepared in 0.125 M 
Tris-HC1, pH6.8, containing 20% (by vol) glycerol (Fi- 
sons, Loughborough, UK),. 4% (w/v )  SDS (Sigma), 10% 
(v /v )  2-mercaptoethanol (Fisons) and bromophenol blue 
(Sigma). Proteins were separated in 12% polyacrylamide 
gels; all lanes were loaded with similar amounts of protein 
[17,18]. Proteins were electrophoretically transferred to 
nitrocellulose membranes (BA 85, Schleicher and SchueU, 
Germany) [19], blocked with 5% dried skimmed milk in 
0.1 M phosphate-buffered saline (PBS), and incubated (5 h 
or overnight, shaken, room temperature) with a rabbit 
polyclonal antiserum raised against rat 3 a-HSD (antiserum 
71536 at 1 /800 - 1 /6400  in PBS, a gift from Professor T. 
Penning, University of Pennsylvania). Antibody bound to 
the membranes was revealed by incubation in 0.1 /xCi/ml 
[125I]-protein A (Amersham Int. plc., Amersham, UK) for 
2 h at room temperature prior to autoradiography at - 70°C. 
2.5. Assay of 3a- and 20o,.-HSD activities in HL60 cells 
The possibility that HL60 cells contained either 3 a-HSD 
or 20a-HSD activities was investigated using established 
assays described previously by Penning et al. [20] and 
Garland and Dexter [21 ], respectively. For 3 a-HSD assays, 
3.1. Indomethacin, aspirin and dexamethasone each poten- 
tiate the differentiation of HL60 cells in response to either 
D 3 or ATRA 
Our previous studies demonstrated that indomethacin 
potentiates the differentiation of HL60 cells treated with 
suboptimal concentrations of ATRA (to neutrophils) and 
of D 3 (to monocytes) [13]. We also showed that dexa- 
methasone potentiates ATRA-induced neutrophilic differ- 
entiation [13]. 
In this study we have shown that dexamethasone (100 
/xM) and aspirin (750 /xM; also an inhibitor of cyclooxy- 
genase) reduce the concentration of D 3 that is required to 
provoke maximal monocyte differentiation from > 50 nM 
to ~ 10-20 nM (Fig. 1): neither agent alone had any 
effect on HL60 cell growth and differentiation. The ob- 
served increases in the percentages of mature cells seen in 
response to D 3 represent increases in the total yields of 
mature monocyte-differentiated cells. Induction of mono- 
cyte differentiation by D 3 was studied using long-term 
serum-free HL60 cultures. This was considered preferable, 
since it avoids the possibility that serum contains agents 
which interact with members of the steroid/thyroid hor- 
mone receptor family. However, as we have described 
previously, ATRA treatment of serum-free HL60 cultures 
results in limited neutrophil differentiation. Therefore, to 
investigate the effects of indomethacin, dexamethasone 
and aspirin on the ATRA concentration that is required for 
maximal neutrophil differentiation serum-maintained HL60 
cells were used in experiments. The potentiation of 
ATRA-induced neutrophil differentiation by indomethacin 
and dexamethasone was reported in our previous study 
[13]. The data from experiments combining ATRA and 
aspirin are shown in Fig. 1. The presence of indomethacin, 
dexamethasone and aspirin reduced ATRA concentration 
needed for maximal maturation towards neutrophils [de- 
fined here as phagocytic cells expressing CDl lb  antigen 
and lacking a-naphthylacetate esterase (ANAE)] from ~ 
100 nM to ~ 10 nM. Serum-grown HL60 cells treated 
with aspirin and ATRA tended to growth-arrest more 
quickly than those in ATRA alone. As a result, there was 
not an increase in the number of neutrophils produced in 
response to < 3 nM ATRA in the presence of aspirin, but 
enhanced numbers of neutrophils were generated at the 
higher ATRA concentrations. 
The sensitivity of HL60 cells to  D 3 and to ATRA was 
not changed by 30 /zM caffeic acid (an inhibitor of 
5-1ipoxygenase), or by 10 /zM thienylethyldihydroxyben- 
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Fig. 1. Potentiation of monocyte and neutrophil differentiation of HL60 
cells by indomethacin, aspirin and dexamethasone. Cultures were seeded 
with 1.106 cells in serum-free medium without D 3 or with D 3 at the 
doses shown, in the presence ( I )  or absence (El) of 20 /xM indo- 
methacin (A and B), 100 /xM dexamethasone (C and D) or 750 /xM 
aspirin (E and F). At day 5, cells were harvested and the proportions with 
the capacity to phagocytose yeasts (A,C,E) and that expressed ANAE 
(B,D,F) were determined. Panels G (phagocytes) and H (NBT reduction- 
positive cells) represent a similar study of the ability of aspirin to 
potentiate ATRA-stimulated neutrophilic differentiation in serum-main- 
tained cells (such effects have already been reported for indomethacin 
and dexamethasone [13]). Data are the means+SE of 4 (l~) and 3 ( I )  
determinations, 
zylidene cyanoacetate (TBA; which inhibits 5-, 12- and 
15-1ipoxygenases) (data not shown). 
3.2. The potentiating effects of  indomethacin, aspirin and 
dexamethasone are not caused by prevention of  prostanoid 
formation 
The above data remained consistent with the original 
hypothesis that the inhibitors promoted differentiation by 
down-regulating the production of  a differentiation-sup- 
pressing prostanoid. Using cells that were labeled for 20 
min. with [14C]arachidonic acid, we analysed the 
prostanoids and other metabolites made by growing and 
differentiating HL60 cells. Products were tentatively iden- 
tiffed by co-migration with standards during TLC. A com- 
plex mixture of  prostanoids was released extracellularly 
(Fig. 2), and the cells retained smaller quantities of  fewer 
prostanoids (not shown). The prostanoid profile of  growing 
serum-maintained cells was similar to that of  growing 
serum-free cells. D3-induced differentiation of  HL60 cells 
to monocytes was accompanied by increased formation of  
all of  the detected arachidonate metabolites: these included 
metabolites that co-migrated with P G F : ,  (maximal in 1-2  
days), PGE 2 (increased mainly during first 2 days), and 
HHT, thromboxane B 2, PGA 2 and PGD 2 (maximum for- 
mation after 2 - 3  days) (Fig. 2). The changes that accom- 
panied neutrophilic differentiation (ATRA plus granulo- 
cyte colony-stimulating factor (G-CSF); [7,13]) were simi- 
lar to those observed in Da-treated cells (not shown). 
Treatment of  growing HL60 cells with 20 /zM indo- 
methacin for 24 h suppressed formation of thromboxane 
B e, PGE e and PGF2~, but did not substantially change the 
formation of  PGD 2 and HHT. 100 /xM dexamethasone 
prevented the formation of  PGE 2 and PGF2, ~ , but had little 
effect on thromboxane B z, PGD e and HHT (Fig. 2). When 
HL60 cells undergoing differentiation were exposed to 
indomethacin or dexamethasone, the increased production 
of  PGE 2, TxB 2 and HHT that occurred during differentia- 
tion was largely abolished and the increase in PGA 2 was 
diminished. Similar effects were seen in cells differentiat- 
ing in response to either D 3 (Fig. 2) or ATRA (not shown). 
These results suggested that HL60 cell differentiation might 
be restrained by one or more of  the drug-sensitive metabo- 
lites, but exogenous PGA 2, PGE 2, PGF:,~ or carbocyclic 
thromboxane A 2 (a stable analogue of  thromboxane A e) 
were not able to prevent indomethacin from potentiating 
differentiation in response to 5 nM D 3 (Table 1). 
3.3. ATRA-mediated priming and indomethacin-mediated 
promotion of  differentiation may involve a shared cellular 
target 
As reported previously, serum-free HL60 cells that are 
treated for up to 4 days with 10 nM ATRA continue to 
grow normally, but show increased responsiveness to D 3 
as an inducer of monocytic differentiation [8]. Since this 
increased sensitivity to D 3 appeared similar to that seen in 
indomethacin-treated cells, experiments were undertaken 
to determine whether the effects of  ATRA 'priming'  and 
of  indomethacin treatment were additive and, therefore, 
likely to occur independently. Alternatively, these various 
agents might act via interference with a common pathway. 
As shown in Fig. 3A indomethacin addition or ATRA 
pretreatment equally potentiated monocytic differentiation 
in response to D 3. However, when indomethacin was 
added to ATRA-primed HL60 cells it did not further 
increase their sensitivity to D 3 (Fig. 3A). Thus, it is likely 
that both treatments interfere with the function of  a single 
HL60 cell component that is involved in regulating the 
sensitivity of  these cells to differentiation-inducing stimuli. 
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Fig. 2. Effects of dexamethasone and indomethacin on the formation of prostanoids during monocytic differentiation. Cultures were induced to undergo 
monocyte differentiation in D 3 alone or in combination with enzyme inhibitors as shown. On days 0-4 ,  107 cells were harvested for labeling and 
separation of prostanoids. The procedures for the labeling of HL60 cells with [Jac]arachidonic acid and for the analysis of metabolites are described in 
Section 2. The positions of authentic prostanoids separated on these plates are shown. The inhihitors had similar effects on the arachidonate metabolite 
profiles of cells (not shown) and of supernatants. 
3.4. 3a-Hydroxysteroid dek,,.ydrogenase as a possible cellu- 
lar target essential for the potentiation of HL60 cell 
differentiation 
In addition to their well-known ability to inhibit 
prostanoid formation, indomethacin, aspirin and dexa- 
methasone are also effective inhibitors of 3~-hydroxy- 
steroid dehydrogenase (3 c~--HSD) [22-25]. Hence, suggest- 
ing this enzyme is another possible target through which 
these 'anti-inflammatory agents' might potentiate HL60 
cell differentiation. We reasoned that if this was the case, 
HL60 cell differentiation would be potentiated by other 
known inhibitors of 3 a-HSD. 
Medroxyprogesterone acetate (MPA) and 17/3-estradiol 
are, respectively, high and relatively low potency steroid 
inhibitors of 3a-HSD [20,2.3]. As shown in Fig. 4, MPA (5 
/zM) potentiated both monocyte and neutrophil differentia- 
tion of HL60 cells in response to  D 3 and ATRA, respec- 
tively. Furthermore, when ATRA priming and MPA treat- 
ment were combined (as in the above experiment with 
indomethacin), they were 11o more effective in potentiating 
differentiation than either treatment alone (Fig. 3B). This 
suggests that MPA influences the same shared intracellular 
target as do ATRA priming and the 'anti-inflammatory 
agents'. 
Estradiol, which is a less potent inhibitor of 3c~HSD 
than MPA [20], was also a less potent potentiator of 
differentiation. Furthermore, estradiol concentrations > 10 
/zM were cytotoxic. For this reason, the effects of estradiol 
were explored both alone and in combination with sub- 
maximally effective doses of indomethacin or dexametha- 
sone. Micromolar concentrations of estradiol had only 
slight effects on differentiation, but estradiol/indo- 
methacin and estradiol/dexamethasone combinations syn- 
ergised in potentiating D3-induced differentiation of HL60 
cells to monocytes (Table 2). For example, only 13-32% 
monocytic cells were obtained with 5 /xM dexametha- 
sone/5 nM D 3 o r  1.9 /zM estradiol/5 nM D3;  but when 
all three agents were present the monocyte yield rose to 
69-75%, close to the maximum monocytic yield (71-82%) 
provoked by the combined use of 10 p~M dexamethasone, 
7.5 ~M estradiol and 5 nM D 3. 
Table 1 
Exogenous prostanoids do not reverse the potentiation of differentiation exhibited by indomethacin 
Agents added in addition to 5 nM D3(5 days) Phagocytic cells (%) NBT-positive cells (%) 
none 
20 /zM indomethacin 
20 /xM indomethacin plus 7 .5/zM PGA 2 
20 /xM indomethacin plus 7.5 ~M  PGE 2 
20 p,M indomethacin plus 7.5 /.Lid PGF 2 ,, 
20 /xM indomethacin plus 7 .5 /zM carbocyclic TxA 2 
1 3 + 1  23+,1  
6 6 + 2  71 +-2 
7 9 + 2  73+_2 
6 4 + 3  9 0 + 2  
60 5:5 79 5:3 
62 + 1 78 5:4 
HL60 cultures were exposed to 5 nM D 3 in the presence of the agents shown. At day 5, cells were harvested and the proportions of cells that phagocytosed 
yeasts and that reduced NBT were determined. The results are percentages of positive cells + S.E. from 3 experiments. 
194 C.M. Bunce et al. / Biochimica et Biophysica Acta 1311 (1996) 189-198 
. 100 
= ~A / N 60 ~ 40 
V 
20  ~- m 
z ~ 0.11 . . . . . . . . . . . .  1 10 
,e lOO n 
so 
-= 60 
=' 40 I 
N 2o 
' 7  
0 . . . . . . . .  I . . . . . . . .  ! 
.1 1 10 
[D3]  nM 
Fig. 3. Potentiation of HL60 differentiation caused by indomethacin and 
'priming' by pretreatment with a low concentration of ATRA are not 
additive. For panel A, HL60 cultures were exposed to  D 3 at the concen- 
trations shown either alone ([2) or in combination with 20 /xM indo- 
methacin (box with center cross). Cultures from HL60 cells that had been 
pretreated with 10 nM ATRA for 3 days were also set in the s a m e  D 3 
concentrations alone (n )  and together with 20 /zM indomethacin (box 
with center dot) (after 4 days, the cultures were harvested and the 
proportion of mature cells present determined by their ability to reduce 
NBT. Data are the mean of 3 experiments, Similar data (not shown) were 
obtained when cells were assessed for their capacity to phagocytose 
yeasts. Panel B shows data from experiments performed in the same way 
as in panel A, but using 5 /xM MPA in place of indomethacin. 
Whereas  5 /xM M P A  potent iated HL60  cell  differentia-  
t ion in a manner  s imilar  to indomethac in  or  dexametha-  
sone, this t reatment  had no effect  on the prostanoid prof i le  
produced by ei ther  uninduced H L 6 0  cells  or cells  that were  
undergoing  differentiat ion towards monocytes  in response 
to D 3 (Fig. 5). Similar ly,  estradiol was not seen to interfere 
with arachidonate  and prostanoid metabo l i sm (not shown).  
These  data re inforce the earl ier  conclus ion that the facilita- 
t ion o f  different iat ion by ant i - inf lammatory  agents such as 
indomethac in  is unrelated to the format ion o f  arachidonate 
metaboli tes .  
3.5. ATRA down-regulates a 3a-HSD-like protein in HL60 
cells, but the cells express no demonstrable 3a-HSD activ- 
ity 
Once  3ce-HSD had been ident i f ied as a possible  target 
of  indomethac in  and A T R A  pr iming,  we explored  its 
expression,  act ivi ty and regulat ion in H L 6 0  cells. The 
tissue distr ibution o f  3 a - H S D  is relat ively poor ly  charac- 
terised, so we  first probed immunoblo t s  of  H L 6 0  cell  
extracts with a rabbit  po lyc lonal  ant ibody raised against  
pure rat l iver  3 a - H S D  [26]. At  di lut ions o f  1 / 3 0 0 0  and 
greater  this ant iserum detected a single polypept ide  of  
~ 34 kDa  (34 + 2 kDa, n = 3). This  polypept ide  is the 
same size as the dominant  immunos ta ined  protein of  rat 
liver, suggest ing that it was l ikely to be mye lo id  cell  
3 a - H S D  (Fig. 6A) or  some other  3 c~-HSD-like aldoketore-  
Table 2 
17fl-estradiol synergises with indomethacin or dexamethasone in potentiating 5 nM D3-induced monocytic differentiation 
Additions (all cultures 
contained 5 nM Dt) 
0 
Indome~haein 1 
(I~VD 2.5 
5 
0 
Dexamethasone I 
(~M) 5 
% phagocytic ceHs 
0 1.9 3.8 7.5 
• B 
• • • • 
• n i • 
,0  . , I n  
% NBT-positive cells % ANAE-positive 
cells 
17~l-estradiol (laM) 
0 1.9 3.8 7.5 
• • , [] 
• • , • 
• , m, mm 
, m m m n  
• . I I  
=III 
I l IN 
0 '  1.9 3.8 7.5 
• , • i 
• • • [ ]  
m i I I 
• • • [ ]  
• • • [] 
IIll 
i l l l  
• , <_-20%; m, 21-30%; i ,  31-40%; • ,  41-50%; i ,  51-60%; i ,  61-70%; i ,  71-80%; i ,  >81% 
HL60 cultures were exposed to 5 nM D 3 in the presence of combinations of estradiol with either indomethacin or dexamethasone, as specified. At day 5, 
cells were harvested and the proportions of cells that phagocytosed yeasts, reduced NBT and that expressed ANAE were determined. The results are 
percentages of positive cells (from 4 sets of control cells and 2 sets of indomethacin and dexamethasone treated cells). 
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ductase. At lower antibody dilutions, a second immuno- 
reactive band ( ~  47 kDa) was also detected (not shown). 
Reactivity of the antiserum with either band was greatly 
diminished by preabsorption with rat liver homogenate or 
when the antiserum was used in the presence of recombi- 
nant 3 a-HSD (not shown). 
Given the evidence that ATRA, the anti-inflammatory 
agents and the steroids described above share a common 
ability to inhibit 3~-HSD and appear to modulate HL60 
differentiation through effects on the same cellular target, 
we examined how ATRA priming affected expression of 
the ~ 34 kDa (3c~-HSD-like) cytosolic protein of HL60 
cells. As we have reported previously, the sensitivity of 
HL60 cells to D 3 rises progressively during 4 days of 
treatment with 10 nM ATRA [8], during which time the 
cells continue to grow normally. During the same period 
the cellular level of the 34 kDa protein detected by the 
anti-3a-HSD antibody was progressively down-regulated 
(Fig. 6B). This suggested tlhat the increased sensitivity of 
the cells to inducers of differentiation after priming with 
~oo~-,< . . . . . . . .  , ~  ~- lOO ,,, 
- -  ; NET _ _ ~ _ _  , O . , - .  ~ ,i. MPA ~ I - I - I ~  
o J > ] i  
II  (. ,  ~,~.,~,.o I ua ._  [ _ .~  [ 
2 0  ~ " t o n t l l t t d  ~ "*0  " 
-0  1 2 3 4 5 {; ae .I I 10 100 
[MPA] uM ,~ IDa] nM 
100 c ~ ~ 1 0 0 ~ - - ~  
,o ¢./%,,,., I" ,or ;" / 
10 100 .1 1 10 100 
[ATRA] nM [O_l nM 
100 - - ]  ~ 100 
o a0 .up ,  n _ 4 u . ~ u ~  o 80 t  0 , ,  , , ,~u.u. . . l .~ 
o ~ 8 
o , o  //..,,./,'°f Z /  ...... 1 
" ,o 1 ,o[ [ 
0 [~ . . . . . . . . . . . . . . .  / ~ O' . . . . . . . . . . . . . . . . . . . . . . . . . .  ' 
10 11)0 .1 1 10 100 
[ATRA] nM [Da] nM 
Fig, 4. Medroxyprogesterone acetate potentiates HL60 cell differentiation. 
(A) Serum-free HL60 cells were treated with 5 nM D 3 alone and in 
combination with the shown concentrations of MPA. At day 5, cells were 
assessed for their ability to phagocytose yeasts and to reduce NBT (see 
Section 2). These data established: that 5 /~M MPA resulted in maximal 
potentiation of HL60 cell differentiation. In subsequent experiments 
serum-free HL60 cells were treated with a range of D3 concentrations 
(panels B, D and F) and serum-maintained HL60 cells were treated with a 
range of ATRA concentrations (C and E) in the presence ( I )  or absence 
( [ ] )  of 5 /*M MPA. At day 5, cells were harvested and assayed for the 
expression of ANAE activity (panel B) and their ability to reduce NBT 
(C and D) and to phagocytose yeasts (E and F). 
Control lOOnM D~ 
AA 
HHT 
PGA: 
PGD.~ 
PGE~ 
TxB,. 
i~i~i!ilili!~ ii~iili~i~i~il I  
ii~iiiil!!i~ ~ii!ii!ii~?~!~i! 
........ i ~i~ ¸ i!~!i~:~! i ¸ 
~iiiiiiiiiiiiiiiiil ~iiiiiii~iiiiii~ 
ii!!ii!ii!~i ...... !~?! ....... 
i!i!iiii!!i!!!!ii 
~iiiiiiiii~ 
AA 
HHT 
PGA2 
PGD2 
PGE2 
TxB 2 
~'i;i!!i i~i!!iiii!!iiiiii!ii!ii 
i?i h ~ ~i~ ~ i ~i~'!i~ii~i~i ? 
iiiiiiiiiiiii!iiiii!ilil 
-MPA +MPA -MPA +MPA 
Fig. 5. Effects of medroxyprogesterone acetate on the formation of 
prostanoids during HL60 monocytic differentiation. Cells induced to 
undergo monocyte differentiation in 100 nM D 3 and control cells were 
cultured alone or in the presence of 5/.LM MPA. On day 3, 107 cells were 
harvested for labeling and separation of prostanoids. The procedures for 
the labeling of HL60 cells with [14C]arachidonic acid and for the analysis 
of metabolites are described in Section 2. The positions of authentic 
prostanoids separated on these plates are shown. 
ATRA might be caused by a decline in the activity or 
concentration of this protein. 
We, therefore, compared the ability of HL60 extracts to 
metabolise dihydrotestosterone (DHT, a standard 3 c~-HSD 
substrate [20]) with DHT reduction by recombinant rat 
3ce-HSD. Recombinant 3a-HSD rapidly inter-converted 
[14C]DHT and [14C]5a-androstane-3a,17fl-diol, as as- 
sessed by TLC, and this reaction was inhibited by either 
indomethacin or MPA, as previously reported (Fig. 7 and 
[20]). As shown in Fig. 7, when HL60 extracts were 
similarly incubated with [14C]DHT, two products were 
observed: one co-chromatographed with androstanediol, 
and the other ran slightly faster. However, indomethacin 
and MPA did not inhibit the accumulation of either of 
these labeled products of []4C]DHT metabolism. This lack 
of inhibition was not simply due to the presence of some 
3-HSD-protective material in the cell extracts, since in 
assays using recombinant 3a-HSD supplemented with 
HL60 cell extracts, indomethacin and MPA remained ef- 
fective. Thus, in this study, we have obtained no conclu- 
sive evidence for the presence of active 3 a-HSD in HL60 
cells. However, whether any part of the observed DHT 
metabolism by HL60 extracts was catalysed by an indo- 
methacin-insensitwe 3a-HSD, or whether it was all at- 
tributable to other routes of metabolism, remains uncertain. 
In future studies, we will address this problem by purifying 
from HL60 cells the enzyme(s) responsible for generating 
the product(s) from DHT which co-migrates with an- 
drostanediol. 
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3.6. Possible involvement of 20c~-hydroxysteroid dehydro- 
genase (20a-HSD) 
20a-HSD is another enzyme of the aldoketoreductase 
family, and is closely related to 3 ce-HSD [27]. More than a 
decade ago, 20~-HSD activity was reported to be present 
in interleukin 3-dependent myeloid cells from bone mar- 
row cultures [21]. We considered whether the immuno-re- 
active protein that is down-regulated during ATRA prim- 
ing might be 20a-HSD. We were unable to detect 
A 
k.Da 34 - 
2 
..EL .KI,_ 
~i ~i~!~i ~i i~ ii~i~i~!i!ii~!i~ii~i~ ......... 
- 117 kDa 
80 
49.5 
32.5 
27 5 
HL60 r3otHSD 
   ::i::iiiiiiiii!iii iii !i!iiii ! ! !i!ii!i iii ! !iS ? ; 
,~:,~:ii~ili:il::iiiiii!:iiiiii!!iSii~:~!  i: . . . . . .  
~ ~ ~: =?~i? ~ 
! 
3o~AD 
control ~'MPA +INI)() contrail +MPA -tlNI')O 
Fig. 7. Metabolism of 5ce-DHT by HL60 cell extracts and recombinant 
3c~-HSD. HL60 cell extracts, prepared as described in Section 2, were 
incubated with [Z4C]5a-DHT in the absence of enzyme inhibitors (con- 
trol) or in the presence of an excess of either MPA (100 /zM) or 
indomethacin (200 /xM). Parallel experiments were performed using 
recombinant 3o~-HSD in place of HL60 cell extracts which generated 
3a-androstanediol (3otAD) in the absence but not in the presence of 
inhibitors. 
120  0 i 2 3 4 5 6 
-- 100 
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,.,~ 40 
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exposure to lOnM ATRA 
(days) 
Fig. 6. 'Priming' doses of ATRA cause down-regulation of the expres- 
sion of a 34 kDa protein recognised by a polyclonal antibody to rat 
3o~-HSD. In Panel A are immunoblots of HL60 (H) and rat liver (RL) 
extracts, showing that HL60 cells contain a polypeptide of ~ 34 kDa that 
is the same size as and that immunologically cross-reacts with rat liver 
3 a -HSD (the procedures for Western blotting are described in Section 2). 
The left most lane shows immunostaining when gels were loaded with 
~ 130 /zg of HL60 protein. The middle and right hand lanes were each 
loaded with ~ 10 /zg of HL60 and rat liver proteins, respectively. For 
panel B, serum-free HL60 cells were treated with 10 nM ATRA for 6 
days. Each day extracts were prepared and immunoblots performed (all 
lanes loaded for equivalent protein) using the antibody to rat 3ot-HSD. 
The amount of reactive protein present was compared by autoradiography 
(see Section 2). Densitometric readings have been normalised to those 
detected in control cells (100%) and are shown as the mean + S.E. of 6 
experiments. The insert shows a typical autoradiograph of the changes in 
the level of the 34 kDa protein. 
metabolism of [14C]progesterone by HL60 cell extracts, 
indicating that these cells contain little or no 20a-HSD. 
4. Discussion 
HL60 promyeloid cells originated from an undifferenti- 
ated myeloid leukaemia, but they retain the ability to 
differentiate efficiently in response to a variety of agents, 
including D 3, ATRA, 9-cis-RA and G-CSF. Thus, they do 
not suffer a total block on differentiation, but somehow 
avoid terminal differentiation which their non-malignant 
counterparts would undergo. 
In our earlier studies, we found that treatment of HL60 
cells with certain 'anti-inflammatory agents' (indo- 
methacin or dexamethasone) causes an approximately ten- 
fold increase in their sensitivity to differentiation-inducing 
agents such as  D 3, ATRA and combined ATRA and 
G-CSF. We speculated that the drugs might prevent cyclo- 
oxygenase-catalysed formation of a differentiation-sup- 
pressive prostanoid [13]. This view seemed to gain in 
credence when we found that aspirin, but not inhibitors of 
arachidonate metabolism via pathways other than cyclo- 
oxygenase, increased the sensitivity of cells to  D 3 and to 
ATRA (see above). However, we have subsequently failed 
to identify an endogenously generated prostanoid that is 
capable of reversing the effect of indomethacin (Table 1). 
When seeking some other mechanism by which these 
anti-inflammatory agents might potentiate differentiation, 
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we noted that 3 c~-hydroxysteroid dehydrogenase (3 a-HSD) 
is another enzyme that is inhibited by indomethacin, dexa- 
methasone and aspirin [22--24]. In addition, we found in 
HL60 cells a protein of the same size as 3 a-HSD (34 kDa) 
that is recognised by a rabbit antiserum to 3a-HSD (rat) 
(Fig. 6). 
Other inhibitors of 3c~-HSD include steroids such as 
medroxyprogesterone acetate (MPA) [20]. Like the anti-in- 
flammatory drugs, MPA also potentiated HL60 differentia- 
tion to monocytes, in response to D 3, and to neutrophils, in 
response to ATRA. Furthermore, the ECs0 for MPA poten- 
tiation of D3-stimulated differentiation (see Fig. 3) was 
similar to the published IC50 for rat brain 3 a-HSD (0.2/xM 
[20]). Estradiol is a less potent steroid inhibitor of 3a-HSD 
and a less potent promotor of HL60 cell differentiation. In 
our experiments, estradiol became toxic at > 10 /xM, so 
we could not accurately determine the ECs0 of its pro-dif- 
ferentiative effect. However, by three measures of mono- 
cytic differentiation, about half maximal differentiation 
occurred between 3.8 /zM and 7.5 /zM estradiol, in the 
presence of 5 nM D 3 (Table 2), pointing to an ECso value 
of ~ 5 /xM. Neither 5/zM MPA nor 7.5/xM estradiol 
interfered with arachidonate metabolism by HL60 cells. 
Thus, the pharmacologica]l profile for inhibition of the 
unidentified HL60 cell component that regulates differenti- 
ation matches that of 3 c~-HSD rather than that of cyclo- 
oxygenase. 
Another treatment that sensitises growing HL60 cells to 
differentiating agents is exposure to a very low dose of 
ATRA [6-8]. The mechanism which underlies this pro- 
cess, known as 'priming',  :remains unknown. The concen- 
tration of ATRA (10 nM) needed for priming neither 
changes the growth rate nor provokes any differentiation 
of serum-free maintained HL60 cells [8]. The effects of 
priming HL60 cells by 1-4 days of exposure to 10 nM 
a l l - t ra n s -RA  or 9 - c i s - R A  are similar to those of the drugs 
just discussed: both treatments increase the sensitivity of 
cells to D 3, so that maximal monocytic differentiation can 
occur in ~ 5 nM D 3 rather than ~ 50 nM D 3 [8,14]. Our 
experiments have shown that full sensitization of the cells 
could be achieved either by ATRA priming or by treat- 
ment with one of the 'anti-inflammatory' and steroid drugs 
discussed above. No further increase in sensitivity oc- 
curred when the two treatments were applied to cells 
simultaneously. This argues that these very different types 
of treatment exert their effects on the same intracellular 
target, or at least on components of the same regulatory 
pathway, in HL60 cells. 
The key question that remains unanswered is the iden- 
tity of the common intracellular target through which 
retinoid priming and these drugs control the sensitivity of 
myeloid cells to differentiation-inducing agents. Although 
this question remains open, it seems highly probable that 
the 3a-HSD-like protein that we have detected immuno- 
logically in HL60 cells is implicated. Although it was 
detected with an anti-3a-HSD antiserum, it may be some 
other enzyme, since we detected no indomethacin or MPA 
sensitive 3a-HSD activity in HL60 cell extracts (these 
extracts allowed recombinant 3 a-HSD to show its normal 
activity). 3a-HSD is a member of the aldoketoreductase 
family of dehydrogenases. As discussed in more detail by 
Deyashiki et al. [27], this is a fairly large group of en- 
zymes with diverse substrates, many members of which 
are of similar molecular size and show high levels of 
polypeptide sequence homology. Consequently it is un- 
likely that the polyclonal antiserum used in this study is 
entirely monospecific for 3 a-HSD. 
The 3~-HSD-like protein that we have detected in 
HL60 cells is an aldoketoreductase that is structurally 
similar enough to 3a-HSD to have similar sensitivity to 
inhibitors and, thus, provide the target for the action of the 
differentiation promoting agents. To account for the pro- 
motion of differentiation by anti-inflammatory agents and 
steroids, we suggest that either its endogenous cellular 
substrate sensitises HL60 cells to differentiating agents or 
its product lowers the responsiveness of these cells to 
differentiating agents. The down-regulation of this protein 
that occurs during ATRA priming fits this model: the 
'primed' cells have largely lost the enzyme, and thus 
behave like cells that have a full enzyme complement that 
has been inactivated by an inhibitor. 
Finally, inhibitors of the activity of the shared molecu- 
lar target of drug-induced sensitization and of ATRA 
priming that we have detected (though not identified) in 
HL60 cells could contribute to clinical treatment of myeloid 
malignancies. Since ATRA and D 3 induce differentiation 
of myeloid leukaemia cell lines such as HL60 and U937 
[1-3,5-7], they have been used in differentiation therapy 
of acute promyelocytic leukaemias and myelodysplasia 
[for reviews see; [28-30]. However, effective therapy has 
tended to need high and relatively toxic doses of ATRA or 
D 3. Our studies raise the possibility that better differentia- 
tion therapy protocols might arise from the use of combi- 
nations of inhibitors of aldoketoreductases with sub-toxic 
concentrations of ATRA or D 3. 
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